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Abstract Stromelysin-1 (MMP-3) is an important member of 
the matrix metalloproteinase family. In joint-degrading diseases 
like arthritis, elevated levels of MMP-3 protein are detected in 
synovial fluid using iimnunological methods. However, these 
methods do not discriminate between active and inactive enzyme. 
In the present study, a specific stromelysin activity assay was 
developed using the selective fluorogenic substrate TNO003 
(Dabcyl-Gaba-Arg-Pro-Lys-Pro-Val-Glu ♦ Nva-Trp-Arg-Glu-
(EDANS)-Ala-Lys-NH2, ♦ = cleavage site). For its use in 
biological media, cleavage of TNO003 by enzymes other than 
stromelysin was effectively blocked by a proteinase inhibitor 
cocktail. Spiking of MMP-3 to synovial fluid resulted in an 
MMP-3 concentration-dependent linear increase in activity. The 
measured MMP-3 activity was not affected by the addition of 
MMP-13, even in a 5-fold excess over MMP-3. Synovial fluid 
from rheumatoid arthritis patients demonstrated 100-fold higher 
levels of active stromelysin than control synovial fluids. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Matrix metalloproteinases (MMP) constitute a family of 
enzymes involved in the degradation of the extracellular ma-
trix in both physiological and pathophysiological turnover of 
tissues. The MMPs comprise four groups [1]: stromelysins 
(MMP-3, -10 and -11), degrading a wide range of substrates, 
collagenases (MMP-1, -8 and -13), which cleave interstitial 
collagen triple helices, gelatinases (MMP-2, and -9), mainly 
acting on unwound collagen and gelatin, and membrane-




Dabcyl, 4-((4-dimethylamino)phenylazo)benzoyl; Dnp, 2,4-dinitro-
phenyl; EDANS, 5-((2-aminoethyl)amino)naphthalene-l-sulfonic 
acid; Mca, (7-methoxycoumarin-4-yl)acetyl; MMP, matrix metallo-
proteinase; Nva, norvaline; RA-SF, synovial fluid of rheumatoid 
arthritis patients; RFU, relative fluorescence units; RP-HPLC, 
reversed phase-high performance liquid chromatography; SC44,463, 
/V-[3-(-7V'-hydroxycarboxamido)2-(2-methylpropyl)propanoyl]-0-
methyl-L-tyrosine-W-methylamide; SF, synovial fluid; TOF-MALD1, 
time-of-flight matrix-assisted laser-desorption ionization 
type MMPs (MMP-14, -15, -16 and -17), which are able to 
activate proMMP-2 (reviewed in [1-3]). 
Of the MMPs, in particular MMP-3 has been implicated as 
playing a pivotal role in joint-degrading diseases like arthritis 
[4,5]. MMP-3 synthesis by chondrocytes and synoviocytes can 
be induced by inflammatory mediators like interleukin-1 [4,6]. 
Highly increased levels of MMP-3 have been found in dis-
eased arthritic cartilage [7], synovium [5,7,8], and synovial 
fluid [9-13]. The other stromelysins, MMP-10 and -11, were 
hardly observed in joint tissues [5,14,15]. MMP-3 is excreted 
in a latent form and, once activated, can degrade a broad 
range of cartilaginous substrates: proteoglycans [16], collagen 
types IX and XI [17], and collagen type II A-telopeptides 
[17,18]. In addition, MMP-3 can participate in the activation 
of proMMP-1, -8, -9 and -13 [19-22], suggesting a key role for 
this enzyme in initiating matrix degradation. 
Levels of MMP-3 in synovial fluid are mostly quantified by 
immunological methods; these do not discriminate between 
active MMP-3 ( < 5% of total), latent forms, and complexes 
with tissue inhibitors of metalloproteinases (TIMPs). Inas-
much as the active fraction of MMP-3 in particular is likely 
to reflect its matrix-degrading capacity, an activity assay 
seems more appropriate. Several stromelysin activity assays 
have been reported; they are based on macromolecular sub-
strates like proteoglycan [23,24], casein [25], and carboxyl-
methylated transferrin [26] or low molecular weight substrates 
such as substance P [27]. These methods mostly involve radio-
activity and/or are not specific for stromelysin [28-30]. Re-
cently, the use of fluorogenic peptides for measuring the ac-
tivity of MMPs including MMP-3 was described [31-33]. 
These substrates consist of a fluorophore and a light-absorb-
ing group (quencher) attached to an amino acid sequence 
recognized by MMPs. Only the sequence reported by Nagase 
et al. [34], Mca-Arg-Pro-Lys-Pro-Val-Gly ♦ Nva-Trp-Arg-
Lys(Dnp)-NH2 ( ♦ =cleavage site), was shown to be preferen-
tially cleaved by MMP-3 compared to other MMPs. Applica-
tion of this substrate in measurements of stromelysin activity 
in biological media has not been reported yet. Previously, we 
have shown that the fluorogenic substrate TN0211, contain-
ing the highly soluble Dabcyl/EDANS as quencher/fluoro-
phore combination, can be conveniently used for MMP activ-
ity measurements in biological media [31]. The present study 
was designed to develop a specific and sensitive stromelysin 
activity assay for biological media, using the fluorogenic 
substrate Dabcyl-Gaba-Arg-Pro-Lys-Pro-Val-Glu4 Nva-Trp-
Arg-Glu(EDANS)-Gly-Lys-NH2 (TNO003), and to investi-
gate whether stromelysin activity levels are elevated in syno-
vial fluid from rheumatoid arthritis patients. 
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2. Materials and methods 
2.1. Substrate TNO003 synthesis 
The fluorogenic substrate Dabcyl-Gaba-Arg-Pro-Lys-Pro-Val-Glu-
Nva-Trp-Arg-Glu(EDANS)-Gly-Lys-NH2 (TNO003) was synthesized 
according to the method described previously [35]. 
2.2. Matrix metalloproteinases 
Human recombinant proMMP-2 (EC 3.4.24.24), proMMP-3 (EC 
3.4.24.17), and proMMP-13 were kindly provided by Dr. P. Mitchell 
(Pfizer Central Research, Groton, CT, USA). The catalytic domain of 
MMP-1 (19 kDa MMP-1, EC 3.4.24.7) was a gift from Dr. J. McGee-
han (Glaxo-Wellcome, Research Triangle Park, NC, USA). The 
19 kDa MMP-1 has the same specific activity for small peptides as 
full-length MMP-1 [36,37] and was therefore assumed to be suitable 
for the present study. MMP-7 was supplied in its active form by Dr. 
P. Cannon (Roche-Syntex, Palo Alto, CA, USA), and proMMP-8 was 
donated by Dr. G. Murphy (Strangeways Laboratories, Cambridge, 
UK). Zymogens were activated by 1 mM APMA (proMMP-2, -3, -8, 
-9) or 2 mM APMA (proMMP-13) for 2 h (proMMP-8, -9, -13) or 16 
h (proMMP-2, -3) at 4°C (proMMP-2) or 37°C (proMMP-3, 8, -9, 
-13) in buffer A, which consisted of 50 mM Tris (pH 7.5), 150 mM 
NaCl, 5 mM CaCl2, 1 uM ZnCl2, and 0.01% Brij-35. The amounts of 
active enzyme were calibrated by active-site titration with TIMP-1 
(MMP-1, -2, -3, -7, -8, and -13) or TIMP-2 (MMP-9) as described 
by others [21,38]. TIMP-1 was a gift from Dr. G. Murphy, and 
TIMP-2 was purchased from Boehringer Mannheim (Germany). 
2.3. Enzyme kinetics: catalytic efficiencies (kcatIKm) 
MMP-1 (10 nM), MMP-2 (5 nM), MMP-3 (5 nM), MMP-7 
(10 nM), MMP-8 (10 nM), MMP-9 (5 nM) and MMP-13 (5 nM) 
were incubated with 2 uM TNO003 at 25°C in buffer A. All incuba-
tions described in this paper had a total volume of 180 ul, and were 
performed in black round bottom 96 well plates (Dynatech, Denken-
dorf, Germany). The increase in fluorescence resulting from substrate 
conversion was followed in a Cytofluor II (excitation filter 360 nm, 
emission filter 490 nm, from PerSeptive Biosystems). Catalytic efficien-
cies (kclit/Km) were calculated from the equation [S]t/[S]o = e
-*', 
with k = [E]tot-(kaa,/Km) [33,39]. Fluorescence after total substrate con-
version (Flumax) is a measure for [S]o, and thus [S]t equals 
Flum a x-Flu t . 
2.4. Reversed phase-high performance liquid chromatography 
(RP-HPLC) 
Purification of the synthetic peptide and separation of cleavage 
products was performed with a Perkin-Elmer Cig Pecosphere 3X3C 
column eluted with a linear acetonitrile (Rathburn, UK) gradient in 
0.1% trifluoroacetic acid (Fluka, Belgium) at 1.0 ml/min delivered by a 
Gynkotek Model 480 pump. Samples were injected with a WISP 
model 710B automated injector (Waters). Detection comprised ab-
sorbance at 215 or at 520 nm (^max of Dabcyl; Applied Biosystems, 
Model 759A) and fluorescence (keyL = 340 nm, Xem = 485 nm, Jasco 
821-FP detector). Identity of the substrate and cleavage products 
was established by TOF-MALDI mass spectrometry [40] (Lasermat, 
Finnigan MAT), and amino acid analysis of collected fractions [41]. 
2.5. Stromelysin activity in synovial fluid: addition of inhibitors 
Synovial fluid from a rheumatoid arthritis (RA-SF) patient was 
centrifuged (4°C, lOOOOXg, 15 min) and the resulting cell-free super-
natant was diluted 5-fold in buffer A. Stromelysin activity in SF 
(finally diluted 20-fold in buffer A) was measured using 5 u,M 
TNO003 (37°C) in the presence of EDTA-free Complete, a mixture 
of non-MMP inhibitors (final concentration: one tablet in 10 ml buff-
er A; Boehringer Mannheim, Germany) to prevent conversion of 
TNO003 by other proteinases than MMPs. All incubations in synovial 
fluid contained this proteinase inhibitor cocktail. 
Further improvement of assay selectivity for MMP-3 was investi-
gated by the addition of the MMP inhibitor SC44,463 (kindly sup-
plied by Dr. P. Mitchell, Pfizer Central Research, Groton, CT, USA), 
which is less potent towards MMP-3 (IC5o = 30 nM; determined in 
buffer) than towards other MMPs (IC50 = 1 nM). IC50 values of 
SC44,463 towards MMP-2, -3, -9, or -13 in synovial fluid were deter-
mined by the addition of SC44.463 (final concentration 0-1000 nM) 
together with the proteinases (2.5 nM). Conversion of TNO003 (5 uM) 
was determined fluorometrically (360/490 nm, Cytofluor II, Perseptive 
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Biosystems); and the activity measured in the absence of SC44,463 
was set at 100%. 
2.6. Stromelysin activity in synovial fluid 
Stromelysin activity in synovial fluid samples from patients with 
rheumatoid arthritis (n = 12) was compared with that in control syno-
vial fluid (obtained post-mortem), from individuals without any sign 
of arthritis (« = 11). Synovial fluids were diluted 5-fold in buffer A 
after centrifugation (4°C, lOOOOXg, 15 min). Stromelysin activity in 
SF (final dilution 20-fold) was measured using 5 uM TNO003 in the 
presence of 300 nM SC44,463 and the Complete inhibitor cocktail 
(final concentration: 1 tablet in 10 ml buffer A). The initial velocity 
of substrate turnover (linear increase in fluorescence over time) was 
used as a measure for enzyme activity. The concentration of active 
stromelysin was calculated using a calibration curve of MMP-3 spiked 
to synovial fluid. 
3. Results 
3.1. Substrate cleavage site 
Addition of stromelysin (MMP-3 , 25 nM) to 4 u M TNO003 
(Dabcyl - G a b a - Arg - Pro - Ly s - Pro - Val-Glu-Nva-Trp-Arg-Glu-
(EDANS)-Gly-Lys-NH 2 ) resulted in a rapid increase in fluo-
rescence indicating substrate conversion. In approximately 
40 min the reaction was completed (Fig. 1A). As expected, 
H P L C analysis (Fig. 2) showed two new peaks at 215 nm. The 
first peak exhibited E D A N S characteristic fluorescence (CS in 
Fig. 2B); the second peak absorbed at 520 nm, indicative of 
Dabcyl (NS in Fig. 2B). Both peaks were analyzed by amino 
acid analysis and by mass spectrometry and identified as 
H-Nva-Trp-Arg-Glu(EDANS)-Gly-Lys-NH 2 and Dabcyl-
Gaba-Arg-Pro-Lys-Pro-Val-Glu-OH, respectively (Fig. 2). 
Thus TNO003 was cleaved at the position indicated ( ♦ ) : 
Dabcyl-Gaba-Arg-Pro-Lys-Pro-Val-Glu ♦ Nva-Trp-Arg-Glu-
(ED ANS)-Gly-Lys-NH 2 . 
Fluorescence after total conversion (as confirmed by 
HPLC) was 27.5-fold higher than the basal fluorescence of 
TNO003. Thus fluorescence of E D A N S in TNO003 was effi-
ciently quenched by Dabcyl (96.4%). The rate of fluorescence 
increase was proport ional to the M M P - 3 concentration (0-2 
n M ; r > 0 . 9 9 , Fig. IB), and low levels of M M P - 3 (down to 
50 pM) could easily be detected by incubating for 60 min. 
3.2. Selectivity of TNO003 towards MMPs 
Determination of the catalytic efficiencies of all M M P s 
available (MMP-1 , -2, -3 , -7, -8, -9, and -13) for TNO003 
Fig. 1. A: Time curve of TNO003 (4 |j,M) hydrolysis by 25 nM 
MMP-3 at 37°C (•). Blank: TNO003 in incubation buffer (o). B: 
MMP-3 activity calibration curve at 37°C. RFU = relative fluores-
cence units. 
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Fig. 2. HPLC analysis of TNO003 and its cleavage products gener-
ated by MMP-3. TNO003 (15 uM) was incubated in the absence 
(A) or presence (B) of 10 nM MMP-3 for 30 min at 22°C. S, the 
parent substrate TNO003 (MH+meas = 2065.7, MH+caic = 2065.4); 
NS, the N-terminal fragment Dabcyl-Gaba-Arg-Pro-Lys-Pro-Val-
Glu-OH (MH+meas = 1061.8, MH+caic = 1060.9); CS, the C-terminal 
fragment Nva-Trp-Arg-Glu(EDANS)-Ala-Lys-NH2 (MH+meas = 
1020.8, MH+calc = 1021.4). 
demonstrated that the substrate is selectively converted by 
MMP-3 (Fig. 3). No activity of MMP-1, -7, and -8 against 
TNO003 could be measured (kcJKm < 1000 M"
1 s_1). MMP-
2, -9 and -13 also hydrolyzed the substrate with kclit/Km values 
but these were substan-
tially lower than for MMP-3 (29000 M"1 s"1). 
ranging from 6000 to 14000 M"1 s"1 
3.3. Stromelysin activity in synovial fluid: enhanced selectivity 
by addition of non-MMP-3 inhibitors 
In biological media, proteinases like plasmin and plasmino-
gen activator may cleave TNO003, due to the presence of Lys-
X and Arg-X bonds. To prevent non-MMP-related activity 
against TNO003, an inhibitor cocktail was added (EDTA-
free Complete). Furthermore, on the basis of their kc&t/Km 
values, MMP-2, -9 and -13 potentially disturb stromelysin 
activity assays in biological media for they also hydrolyze 
TNO003 albeit at a slower rate than MMP-3. To block this 
non-stromelysin activity, the synthetic MMP inhibitor 
SC44,463 was used. In buffer, its IC50 value for MMP-3 is 
approximately 30 times higher than for other MMPs 
(IC50 ~ 1 nM). To investigate whether this 30-fold difference 
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-13 
Fig. 3. Catalytic efficiencies (kCBt/Km) for conversion of TNO003 by 
MMPs at 25°C. Mean ± S.D. of three separate experiments are 
shown. 
in IC50 value is also valid for synovial fluid, IC50 values of 
SC44,463 were determined in RA-SF against MMP-3, -2, -9 
and -13. These MMPs (2.5 nM) were spiked to RA-SF, to-
gether with the non-MMP inhibitor cocktail (Complete) and 
SC44,463 ranging from 0 to 1000 nM. MMP-2, -9 and -13 
were profoundly inhibited by SC44,463 with IC50 values of 
50-200 nM (Fig. 4A). No inhibition of MMP-3 was observed, 
even at the highest inhibitor concentration tested (1 |J,M). 
Therefore, in all subsequent stromelysin activity assays, 
SC44,463 was added at 300 nM to minimize substrate turn-
over by MMPs other than stromelysin. 
So far, only non-activated synovial fluids were used. How-
ever, most of the stromelysin present in synovial fluid will be 
in the inactive pro-form. In five synovial fluids, prostromely-
sin was activated with the mercurial compound APMA [42] 
resulting in a 2-24-fold increase in activity (result of one SF 
sample shown in Fig. 4B). The stromelysin activity could be 
blocked by the potent MMP inhibitor BB94 (10 uM), indicat-
ing that indeed stromelysin activity is measured. 
3.4. Effect of MMP-13 addition on measured stromelysin 
activity in synovial fluid 
Regarding the selective inhibition of SC44,463 and the low-
er kcJKm of MMP-2, -9 and -13 for TNO003 than MMP-3, 
our stromelysin activity assays in biological media are unlikely 
to be disturbed by non-stromelysins. To ensure, however, that 
such MMPs do not interfere in this assay, a concentration 
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Fig. 4. A: Inhibitory capacity of the MMP inhibitor SC44,463 towards conversion of TNO003 (5 uM) by MMP-2, -3, -9 and -13 (2.5 nM) 
added to synovial fluid from a rheumatoid arthritis patient. MMP activity (rate of conversion of TNO003) in the absence of SC44,463 was set 
at 100%. B: Stromelysin activity in RA-SF; effect of activation by APMA (1 mM, 20 h, 37°C; activ. RA-SF) and the MMP inhibitor BB94 
(10 uM). C: Influence of MMP-13 on the stromelysin activity measured in synovial fluid. The activity of MMP-3 (0-2 nM) added to synovial 
fluid from a rheumatoid arthritis patient was measured in the presence and absence of MMP-13 (2.5 nM; see Section 2 for details). 
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Fig. 5. Levels of active stromelysm in synovial fluid from control 
subjects (no sign of arthritis) and from patients suffering from rheu-
matoid arthritis were determined using the developed TNO003-
based activity assay. Closed symbols are individual data, open sym-
bols represent the group mean±S.D.; see Section 2 for details. Stu-
dent's (-test was used for statistical analysis. 
range of MMP-3 (0-2 nM) was added to RA-SF and the 
activity against TNO003 was measured in the presence and 
absence of 2.5 nM MMP-13 (Fig. 4C), which is the most 
disturbing enzyme regarding its kclAIKm for TNO003. Under 
the test conditions with Complete and SC44,463 the conver-
sion rate of TNO003 by MMP-3 was not affected by the 
presence of MMP-13, even when a 5-fold excess of MMP-13 
(2.5 nM) over MMP-3 (0.5 nM) was used. This indicates that 
only stromelysin activity is determined in this TNO003-based 
assay format. 
3.5. Stromelysin activity in control SF compared with RA-SF 
The activity assay with TNO003 was applied to synovial 
fluid obtained from rheumatoid arthritis patients (RA-SF) 
and from control subjects (C-SF). The concentration of active 
stromelysin was calculated using a calibration curve of MMP-
3 in synovial fluid. Virtually no stromelysin activity was ob-
served in control SF samples (0.3 ±0.5 nM stromelysin, 
n- 11). All synovial fluids from rheumatoid arthritis patients 
(n - 12) contained a considerable amount of active stromelysin 
(28.6 ±24.1 nM), approximately 100-fold higher than in syno-
vial fluids of control subjects ( P < 0.001, Fig. 5). 
4. Discussion 
The present report describes the development of a specific 
assay for stromelysin activity in synovial fluid, using a selec-
tive fluorogenic substrate in combination with non-stromely-
sin inhibitors. The use of fluorogenic substrates together with 
the application in 96-well plates provides rapid and conven-
ient measurements and allows a high sample throughput. Ad-
ditionally, the assay can be applied in other biological media, 
involves no species-specific antibodies, and is therefore not 
limited to human samples. 
SC44,463, an MMP inhibitor used to block MMPs other 
than MMP-3, showed markedly higher IC50 values (50-200-
fold) in synovial fluid compared with those found in buffer. 
Most likely, this is due to a decrease in free SC44,463 in 
synovial fluid as a result of protein binding. This interaction 
with proteins may well be variable depending on physico-
chemical properties of the MMP inhibitor. This implies that 
the therapeutic efficiency of MMP inhibitors in joint-degrad-
ing diseases can differ from the inhibiting potency found in 
buffer. Therefore, screening of MMP inhibition by synthetic 
compounds in synovial fluid is likely to be more valuable than 
assaying in buffer since the SF data obtained better reflect the 
interaction between enzyme and inhibitor in vivo. 
Recently, we found a 20-fold higher overall MMP activity 
in rheumatoid synovial fluid than in controls with the general 
fluorogenic MMP substrate TN0211 [31]. Here, we show that 
the activity of one particular MMP, stromelysin, is even 100-
fold higher. Thus, expression and activation of stromelysin in 
rheumatoid arthritis seems to be higher than that of total 
MMPs. 
Since only active stromelysin is detected, this type of assay 
can be regarded as more useful than immunological methods 
where antibodies also recognize inhibited forms of stromelysin 
[9,11-13]. Thus the stromelysin activity assay provides a novel 
tool for investigating whether stromelysin enzyme activity is 
of diagnostic or prognostic value in monitoring joint destruc-
tion in arthritides. 
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